Michael D. Green

Active 1980–2025

Also published as
Michael D Green
98
Papers
18,082
Citations
55
h-index
95
i10-index

Citations

Citations per year for Michael D. Green1981: 1 citations1982: 1 citations1983: 11 citations1984: 11 citations1985: 9 citations1986: 9 citations1987: 8 citations1988: 9 citations1989: 37 citations1990: 14 citations1991: 19 citations1992: 22 citations1993: 19 citations1994: 20 citations1995: 18 citations1996: 19 citations1997: 34 citations1998: 28 citations1999: 34 citations2000: 25 citations2001: 42 citations2002: 41 citations2003: 29 citations2004: 27 citations2005: 38 citations2006: 49 citations2007: 70 citations2008: 77 citations2009: 60 citations2010: 67 citations2011: 61 citations2012: 62 citations2013: 92 citations2014: 102 citations2015: 99 citations2016: 79 citations2017: 96 citations2018: 99 citations2019: 343 citations2020: 498 citations2021: 788 citations2022: 857 citations2023: 773 citations2024: 1,121 citations2025: 609 citations2026: 16 citations

Citation sources

Countries

World map of the countries and regions citing this authorChina: 2,276 citing papers, 28.1% of this breakdownUnited States: 1,881 citing papers, 23.2% of this breakdownUnited Kingdom: 410 citing papers, 5.1% of this breakdownGermany: 280 citing papers, 3.4% of this breakdownFrance: 254 citing papers, 3.1% of this breakdownItaly: 243 citing papers, 3% of this breakdownAustralia: 192 citing papers, 2.4% of this breakdownCanada: 188 citing papers, 2.3% of this breakdownNetherlands: 184 citing papers, 2.3% of this breakdownJapan: 183 citing papers, 2.3% of this breakdownSwitzerland: 143 citing papers, 1.8% of this breakdownSpain: 141 citing papers, 1.7% of this breakdown
0%28.1%Other 21.3%

Fields

  • Medicine66%
  • Biochemistry, Genetics and Molecular Biology17.2%
  • Immunology and Microbiology9.5%
  • Engineering3.5%
  • Chemistry1%
  • Materials Science0.3%
  • Other2.5%

Topics

  • Ferroptosis and cancer prognosis9.1%
  • Cancer Immunotherapy and Biomarkers6.4%
  • Immune cells in cancer3.9%
  • RNA modifications and cancer3.7%
  • Cancer, Lipids, and Metabolism3.3%
  • Immunotherapy and Immune Responses2.3%
  • Other71.3%

Coauthors

All papers

Open in search
  1. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2019 cited by 2,909

  2. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2019 cited by 1,054

  3. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ilona Kryczek, T. Vincent, Christopher D. Lao, Theodore S. Lawrence, Nithya Ramnath, Fei Wen, Arul M. Chinnaiyan, Marcin Cieślik, Ajjai Alva, Weiping Zou - Nature Medicine 2021 cited by 973

  4. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2023 cited by 147

  5. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2018 cited by 602

  6. Metabolism drives macrophage heterogeneity in the tumor microenvironment

    Authors: , , , , , , , , , , , , , , , - Cell Reports 2022 cited by 163

  7. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2021 cited by 156

  8. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2020 cited by 200

  9. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sohrab P. Shah, Andrew McPherson, Katherine S. Panageas, Jason S. Lewis, Justin S. A. Perry, Elisa de Stanchina, Triparna Sen, John T. Poirier, Jedd D. Wolchok, Charles M. Rudin, Taha Merghoub - Cancer Cell 2021 cited by 175

  10. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy

    Authors: , , , , , , - Cellular and Molecular Immunology 2021 cited by 142

  11. The Liver–Immunity Nexus and Cancer Immunotherapy

    Authors: , , , , , - Clinical Cancer Research 2021 cited by 115

  12. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells

    Authors: , , , , , , , , , , - Nature Biotechnology 2013 cited by 586

  13. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary

    Authors: , , , , , , , , , , , , , , , , , , , , - Kidney International 2009 cited by 1,733

  14. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy

    Authors: , , , , , , , , , , , , , , , , - Cancer Research 2019 cited by 243

  15. Efficient Derivation of Purified Lung and Thyroid Progenitors from Embryonic Stem Cells

    Authors: , , , , , , , , , , , , , , , , - Cell stem cell 2012 cited by 391

  16. Generation of anterior foregut endoderm from human embryonic and induced pluripotent stem cells

    Authors: , , , , , , , , - Nature Biotechnology 2011 cited by 391

  17. The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells

    Authors: , , , , , , - Nature Protocols 2015 cited by 215

  18. Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2023 cited by 35

  19. Contribution of Lipid Oxidation and Ferroptosis to Radiotherapy Efficacy

    Authors: , , , , - International Journal of Molecular Sciences 2021 cited by 38

  20. Impact of poor-quality medicines in the ‘developing’ world

    Authors: , , - Trends in Pharmacological Sciences 2010 cited by 281

  21. Oxidative Stress in Malaria

    Authors: , , , , , , , , - International Journal of Molecular Sciences 2012 cited by 362

  22. Guidelines for Field Surveys of the Quality of Medicines: A Proposal

    Authors: , , , , , , , , , , , , , , , - PLoS Medicine 2009 cited by 213

  23. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the National Comprehensive Cancer Network 2021 cited by 53

  24. Insights from in vivo preclinical cancer studies with histotripsy

    Authors: , , , , , , - International Journal of Hyperthermia 2024 cited by 32